ArticleActa obstetricia et gynecologica Scandinavica2020
Validation of the 34-week gestation as definition of late onset preeclampsia: Testing different cutoffs from 30 to 37 weeks on a population-based cohort of 1700 preeclamptics.
Article in Acta obstetricia et gynecologica Scandinavica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Maternal and Early Neonatal Serum Cytokine and Endothelin-1 Concentrations in Preeclampsia: A Single-Center Observational Cohort Study.Children (Basel, Switzerland) · 2026Article
- Placental plasminogen activator inhibitor 1 is induced by platelet-derived TGF-β independently of TGF-β receptor 3 and is upregulated in preeclampsia.Molecular human reproduction · 2026Article
- Large-Scale Proteomics Reveals New Candidate Biomarkers for Late-Onset Preeclampsia.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Preeclampsia 2.0: limitations and challenges of the two-stage hypothesis, and beyond.Molecular human reproduction · 2026Review
- Inhibitory immune checkpoints in preeclampsia: current landscape, mechanisms, and clinical perspectives.Frontiers in immunology · 2026Review
- The placental maturation inflection point: an integrative biological framework for understanding early-onset versus late-onset preeclampsia.Frontiers in endocrinology · 2026Review
- Signs of immune dysregulation in second-trimester maternal blood RNA profiles in late-onset preeclampsia.Scientific reports · 2025Article
- Human Placental Genomic Instability Predicts Adverse Pregnancy Outcomes.Research square · 2025Article
- Rotational Thromboelastometry (ROTEM) Hemostasis Profile in Pregnant Women with Preeclampsia and Their Offspring: An Observational Study.Diagnostics (Basel, Switzerland) · 2025Article
- [The new S2k guidelines on hypertensive diseases during pregnancy (HES): diagnosis and treatment-What do anesthetists need to know?]Die Anaesthesiologie · 2025Review
- Heme oxygenase/carbon monoxide system affects the placenta and preeclampsia.Medical gas research · 2025Review
- Therapeutic potential of extracellular vesicles for treating human pregnancy disorders.Extracellular vesicles and circulating nucleic acids · 2025Review
- Exploring the Spectrum of Electrolyte Imbalances in Preeclampsia: Mechanisms, Implications, and Clinical Insights.Cureus · 2024Review
- Pregestational maternal risk factors for preterm and term preeclampsia: A population-based cohort study.Acta obstetricia et gynecologica Scandinavica · 2023Article
- Pre-eclampsia.Nature reviews. Disease primers · 2023Review
- Prediction of pre-eclampsia at St. Mary's hospital lacor, a low-resource setting in northern Uganda, a prospective cohort study.BMC pregnancy and childbirth · 2023Article
- Galectins: Important Regulators in Normal and Pathologic Pregnancies.International journal of molecular sciences · 2022Review
- The Role of Inorganics in Preeclampsia Assessed by Multiscale Multimodal Characterization of Placentae.Frontiers in medicine · 2022Article
- Galectins in Early Pregnancy and Pregnancy-Associated Pathologies.International journal of molecular sciences · 2021Review
- Nocturnal hypertension and risk of developing early-onset preeclampsia in high-risk pregnancies.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
introductionEarly onset preeclampsia (EOP) and late onset preeclampsia (LOP) have been differentiated with a cut-point of ≤34 weeks. This classical definition has never been examined with respect to maternal characteristics by different gestational age cut-points. We examined maternal characteristics in a population-based cohort of 1736 preeclamptic deliveries at different gestational age cut-points from 30 to 37 weeks (CO30 to CO37). MATERIAL AND
methodsEighteen-year observational population-based historical cohort study (2001-2018). All consecutive births delivered at the Centre Hospitalier Universitaire Hospitalier Sud Reunion's maternity. Standardized epidemiological perinatal database.
resultsThe incidence of EOP was lower in adolescents (1.8% vs 3.5%, odds ratio [OR] 0.50, P = .17). Conversely, the odds of LOP was increased for women over 35, beginning at C030 (OR 1.13, P = .02) and this effect (OR = 1.2) was still detectable at C037 (P = .06). Among primigravid women, the incidence of EOP was lower than LOP (OR ranging from 0.71 to 0.82 for different CO). Conversely, the incidence of LOP was higher (adjusted OR about 2.7 [CO30-CO34] with a rise to 3.3 at CO37 (P < .001). Women with EOP had a lower body mass index (BMI) as compared with LOP at CO34 and CO37. The adjusted OR (per 5 kg/m
conclusionsThe 34th week of gestation appears to provide a reasonable cut-point to differentiate between EOP and LOP. Additional research is needed to better describe the possible differences in the pathophysiology of these different phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.